Cordlife Group Limited (CLIFF) Stock Price & Analysis
Cordlife Group Limited (CLIFF) — price $0.1283 (0.00%), as of the Nov 19, 2026 trading session; market cap $32.9M.
Educational signal · not a buy or sell recommendation · How to read this
Cordlife Group Limited · CLIFF
Cordlife Group Limited is an investment holding company providing cord blood banking and a range of diagnostic services across Singapore, Hong Kong, India, Malaysia, and the Philippines. The company specializes in stem cell processing and storage, alongside non-invasive prenatal and newborn genetic screenings, serving international healthcare markets.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.1283 | |
| Change on the day | 0.00% | |
| Market capitalisation | $32.9M | |
| Shares traded on the day | 2.1K |
Price & events
Other perspectives
Council score for Cordlife Group (CLIFF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Cordlife Group (CLIFF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Cordlife Group Limited (CLIFF) is the company analyzed here. In Q2 FY2026 it reported revenue of S$8M and net income of -S$936,000. The market values it at $32.9M.
What do the latest results show for Cordlife Group (CLIFF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of S$8M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | S$8M | -S$936,000 | -S$0.0037 (diluted) |
| Q1 FY2026 | S$9M | -S$2M | -S$0.01 (diluted) |
| Q4 FY2025 | S$9M | -S$6M | -S$0.02 (diluted) |
| Q3 FY2025 | S$10M | -S$2M | -S$0.01 (diluted) |
What are the financial strengths and risks for Cordlife Group (CLIFF)?
Short answer · as of
The distress and quality screens read Altman Z 0.69 · Piotroski F 2. Trailing ratios: ROE -10.3% · ROA -5.4% · current ratio 2.84 · earnings yield -45.8% · free-cash-flow yield -4.2%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.69 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-10.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CLIFF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CLIFF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About CLIFF
These answers are editorial: 1 of these 8 answers is drawn from the CLIFF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is CLIFF a good stock to buy?
Stock Expert AI does not rate CLIFF buy, sell or hold. Cordlife Group Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CLIFF stock price today?
The last price recorded for Cordlife Group Limited (CLIFF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Cordlife Group Limited do?
Cordlife Group Limited is a Singapore-headquartered investment holding company that specializes in two primary healthcare segments: Banking and Diagnostics. In its Banking segment, the company provides comprehensive services for the processing and long-term cryogenic storage of stem cells derived from cord blood, cord lining, and cord tissue.
What are the key factors to evaluate for CLIFF?
Evaluate CLIFF on fundamentals, analyst consensus, and risk factors. The company currently does not offer a dividend yield, aligning with its growth-focused operational strategy and potentially reinvesting earnings back into the business. Not financial advice.
How frequently does CLIFF data refresh on this page?
CLIFF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CLIFF's recent stock price performance?
Cordlife Group Limited (CLIFF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified service portfolio encompassing both stem cell banking and a broad range of diagnostic tests. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CLIFF overvalued or undervalued right now?
Cordlife Group Limited (CLIFF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CLIFF before investing?
Before investing in Cordlife Group Limited (CLIFF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 10 figures on this page — 8 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com